RSI breakout - 20ma brake above - 17p / 23.6p targetsvolume spike today on no news, looking rather strong if close above 20ma this week.
looks like it's breaking the down trend.
17p 1st target
23.6p 2nd target area
Next report date
Report period
H2 2024
EPS estimate
−0.01USD
Revenue estimate
35.10 MUSD
−0.0372USD
−54.67 MUSD
75.63 MUSD
159.68 M
About ALLERGY THERAPEUTICS ORD GBP0.001
Sector
CEO
Manuel Llobet
Headquarters
Worthing
Website
Employees (FY)
612
Founded
2004
ISIN
GB00B02LCQ05
FIGI
BBG000Q74FF1
Allergy Therapeutics Plc is a biotechnology company, which engages in the Research and Development of allergy treatments. The company was founded by Keith Iain Carter in 1998 and is headquartered in Worthing, the United Kingdom.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of AGYTF is 0.0200 USD — it hasn't changed in the past 24 hours. Watch Allergy Therapeutics Plc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Allergy Therapeutics Plc. stocks are traded under the ticker AGYTF.
Allergy Therapeutics Plc. is going to release the next earnings report on Sep 25, 2024. Keep track of upcoming events with our Earnings Calendar.
AGYTF stock is 0% volatile and has beta coefficient of 1.68. Track Allergy Therapeutics Plc. stock price on the chart and check out the list of the most volatile stocks — is Allergy Therapeutics Plc. there?
AGYTF earnings for the last quarter are −0.02 USD per share, whereas the estimation was −0.01 USD resulting in a −50.01% surprise. The estimated earnings for the next quarter are −0.01 USD per share. See more details about Allergy Therapeutics Plc. earnings.
Allergy Therapeutics Plc. revenue for the last quarter amounts to 48.26 M USD despite the estimated figure of 48.26 M USD. In the next quarter revenue is expected to reach 31.73 M USD.
Yes, you can track Allergy Therapeutics Plc. financials in yearly and quarterly reports right on TradingView.
AGYTF net income for the last quarter is −19.92 M USD, while the quarter before that showed −43.87 M USD of net income which accounts for 54.59% change. Track more Allergy Therapeutics Plc. financial stats to get the full picture.
Today Allergy Therapeutics Plc. has the market capitalization of 171.76 M, it has increased by 0.84% over the last week.
No, AGYTF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, AGYTF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Allergy Therapeutics Plc. stock right from TradingView charts — choose your broker and connect to your account.
AGYTF reached its all-time high on Nov 4, 2021 with the price of 0.5390 USD, and its all-time low was 0.0001 USD and was reached on Oct 21, 2020. View more price dynamics on AGYTF chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
As of May 5, 2024, the company has 612.00 employees. See our rating of the largest employees — is Allergy Therapeutics Plc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Allergy Therapeutics Plc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Allergy Therapeutics Plc. stock shows the sell signal. See more of Allergy Therapeutics Plc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Allergy Therapeutics Plc. EBITDA is −45.75 M USD, and current EBITDA margin is −51.40%. See more stats in Allergy Therapeutics Plc. financial statements.